Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
NodThera
Biotech
Rezera revs up for $181M IPO to fund NLRP3 inhibitor ph. 3 trial
Rezera—the new name for NodThera—is aiming for a $181 million IPO to take its NLRP3 inhibitor into phase 3 trials for a cardiovascular disease.
James Waldron
Nov 5, 2026 10:15am
Rebranded NodThera plans IPO to fund NLRP3 inhibitor program
Oct 22, 2026 5:27am
Moderna CMO steps down in leadership mix-up—Chutes & Ladders
Feb 6, 2026 8:30am
Introducing Fierce Biotech's 2024 Fierce 15
Aug 5, 2024 6:00am
NodThera's NLRP3 inhibitor shows obesity promise in early trial
Jun 12, 2024 7:00am
NodThera's NLRP3 inhibitor nearly matches Wegovy for weight loss
Feb 21, 2024 8:30am
